Search results
Showing 1 to 15 of 21 results for semaglutide
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Awaiting development [GID-TA10438] Expected publication date: TBC
NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA910
In development [GID-TA11544] Expected publication date: TBC
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Oral semaglutide for managing overweight and obesity [ID6188]
Awaiting development [GID-TA11149] Expected publication date: TBC
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458
Awaiting development [GID-TA11477] Expected publication date: TBC
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....
This guideline covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults.
In development [GID-TA11104] Expected publication date: TBC